Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Daptomycin
Drug ID BADD_D00581
Description Daptomycin is a cyclic lipopeptide antibacterial agent with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and -resistant _Staphylococcus aureus_ (MSSA/MRSA) and vancomycin-resistant Enterococci (VRE).[A231379, A231384, L32534] Chemically, daptomycin comprises 13 amino acids, including several non-standard and D-amino acids, with the C-terminal 10 amino acids forming an ester-linked ring and the N-terminal tryptophan covalently bonded to decanoic acid.[A231374, L32534] Daptomycin was first discovered in the early 1980s by researchers at Eli Lilly in soil samples from Mount Ararat in Turkey.[A231384] Early work on developing daptomycin was abandoned due to observed myopathy but was resumed in 1997 when Cubist Pharmaceuticals Inc. licensed daptomycin; it was found that a once-daily dosing scheme reduced side effects while retaining efficacy.[A231379] Daptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN® by Cubist Pharmaceuticals LLC (Merck & Co.).[L32534]
Indications and Usage For the treatment of complicated skin and skin structure infections caused by susceptible strains of Gram-positive microorganisms.
Marketing Status Prescription; Discontinued
ATC Code J01XX09
DrugBank ID DB00080
KEGG ID D01080
MeSH ID D017576
PubChem ID 16134395
TTD Drug ID D05HPI
NDC Product Code 71288-016; 0143-9378; 0703-0125; 0409-5933; 42513-0015; 16729-434; 67254-515; 73402-111; 31722-102; 0409-0122; 43598-413; 63323-585; 71288-017; 71839-107; 68225-082; 43598-476; 42513-0004; 72572-100; 69097-850; 0409-2757; 60977-145; 68225-052; 25021-174; 67919-012; 57885-0011; 25021-179; 72572-102; 69097-807; 70594-034; 51187-0002; 0409-0120; 67184-0549; 16714-892; 17337-0261; 60505-6229; 67457-813; 63323-871; 0781-3295; 71288-018; 16729-435; 63323-371; 68001-467; 68001-376; 55150-344; 70594-053; 71839-108; 67919-011
Synonyms Daptomycin | Deptomycin | Cubicin | Daptomycin, 9-L beta-Aspartic Acid | Daptomycin, 9 L beta Aspartic Acid | LY-146032 | LY 146032 | LY146032
Chemical Information
Molecular Formula C72H101N17O26
CAS Registry Number 103060-53-3
SMILES CCCCCCCCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC3C(OC (=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC3=O)CCCN)C C(=O)O)C)CC(=O)O)CO)C(C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gastrointestinal pain07.01.05.005--
Generalised oedema14.05.06.007; 08.01.07.0040.000319%
Gingival pain07.09.04.001--
Glossitis07.14.01.001--Not Available
Haemoglobin decreased13.01.05.003--Not Available
Haemolysis01.06.04.0020.000319%
Haemolytic anaemia01.06.03.0020.000319%Not Available
Haemoptysis24.07.01.006; 22.02.03.004; 02.01.02.0060.000319%Not Available
Hallucination19.10.02.002--
Headache17.14.01.001--
Heart rate increased13.14.04.0020.000532%Not Available
Hepatic failure09.01.03.0020.000278%
Hepatic function abnormal09.01.02.0010.000426%Not Available
Hepatitis09.01.07.0040.000532%Not Available
Hepatitis acute09.01.07.0050.000213%Not Available
Hepatitis cholestatic09.01.01.0020.000319%Not Available
Hepatitis fulminant11.07.01.003; 09.01.07.0070.000083%Not Available
Hepatocellular injury09.01.07.0080.000426%Not Available
Hepatotoxicity09.01.07.009; 12.03.01.008--Not Available
Hyperglycaemia14.06.02.002; 05.06.02.0020.000319%
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkalaemia14.05.03.0010.000426%
Hypersensitivity10.01.03.003--
Hypersensitivity vasculitis24.05.02.012; 23.06.02.005; 10.02.02.017; 01.01.04.0080.000532%Not Available
Hypertension24.08.02.001--
Hypoaesthesia17.02.06.023--Not Available
Hypocalcaemia14.04.01.0040.000213%
Hypoglycaemia14.06.03.001; 05.06.03.0010.000426%
Hypokalaemia14.05.03.002--
Hypomagnesaemia14.04.02.001--
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 13 Pages